Quick Takeaways
- Avoro Capital Advisors LLC filed SCHEDULE 13G/A for BIOCRYST PHARMACEUTICALS INC Common Stock, $0.01 par value (BCRX).
- Disclosed ownership: 4.2%.
- Date of event: 31 Mar 2025.
Avoro Capital Advisors LLC - 31 Mar 2025 SCHEDULE 13G/A Report for BIOCRYST PHARMACEUTICALS INC Common Stock, $0.01 par value (BCRX)
- Filing Manager
- Avoro Capital Advisors LLC
- Reporting Manager
- Avoro Capital Advisors LLC
- Symbol
- BCRX
- Shares outstanding
- 207,142,857 shares
- Disclosed Ownership
- 8,700,000 shares
- Ownership
- 4.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 09:31:29 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Avoro Capital Advisors LLC disclosed 4.2% ownership in BIOCRYST PHARMACEUTICALS INC Common Stock, $0.01 par value (BCRX) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 09:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 4.2% | 8,700,000 | 8,700,000 | 0 | /s/ Scott Epstein | Scott Epstein, Chief Financial Officer & Chief Compliance Officer | |
| Behzad Aghazadeh | 4.2% | 8,700,000 | 8,700,000 | 0 | /s/ Behzad Aghazadeh | Behzad Aghazadeh, Individually |